Bausch Health Finalizes $63 Million Purchase of DURECT, Enhancing AH Therapy Portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 11 2025
0mins
Source: NASDAQ.COM
Acquisition Details: Bausch Health Companies Inc. has completed its acquisition of DURECT Corporation for $1.75 per share, totaling approximately $63 million, with potential milestone payments of up to $350 million based on future sales.
Focus on Liver Disease: The acquisition includes larsucosterol, a promising treatment for alcohol-associated hepatitis, which currently has no approved therapies and a high mortality rate; a Phase 3 trial is planned to assess its efficacy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
